Octreotide-modified liposomes containing daunorubicin and dihydroartemisinin for treatment of invasive breast cancer
Source abstract
Abstract
Tumor invasion is considered a major promoter in the initiation of tumor metastasis, which is supposed to cause most cancer-related deaths. In the present study, octreotide (OCT)-modified daunorubicin plus dihydroartemisinin liposomes were developed and characterized. Evaluations were undertaken on breast cancer MDA-MB-435S cells and MDA-MB-435S xenografts nude mice. The liposomes were ∼100 nm in size with a narrow polydispersity index. In vitro results showed that the OCT-modified daunorubicin plus dihydroartemisinin liposomes could enhance cytotoxicity and cellular uptake by OCT-SSTRs (somatostatin receptors)-mediated active targeting, block on tumor cell wound healing and migration by incorporating dihydroartemisinin. The action mechanism might be related to regulations on E-cadherin, α5β1-integrin, TGF-β1, VEGF and MMP2/9 in breast cancer cells. In vivo, the liposomes displayed a prolonged circulating time, more accumulation in tumor location, and a robust overall antitumor efficacy with no obvious toxicity at the test dose in MDA-MB-435S xenograft mice. In conclusion, the OCT-modified daunorubicin plus dihydroartemisinin liposomes could prevent breast cancer invasion, hence providing a possible strategy for treatment of metastatic breast cancer.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Neuroendocrine Tumor Research Advances · Nanoparticle-Based Drug Delivery · Lung Cancer Research Studies
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutical Engineering, Beijing Institute of Petrochemical Technology
School of Pharmacy, Liaoning University of Traditional Chinese Medicine
Funding
National Natural Science Foundation of China · Education Department of Liaoning Province
References (46)
Show source-provided references
1. 10.1002/ijc.2373610.1002/ijc.23736 ↗
2. 10.2147/PPA.S4222310.2147/PPA.S42223 ↗
3. 10.3892/ol.2017.602510.3892/ol.2017.6025 ↗
4. Yang X, Shi L, Yi C, et al. MiR-210-3p inhibits the tumor growth and metastasis of bladder cancer via targeting fibroblast growth factor receptor-like 1. Am J Cancer Res. 2017;7:1738–1753.
5. 10.3322/caac.2133210.3322/caac.21332 ↗
6. 10.1186/s13046-015-0277-810.1186/s13046-015-0277-8 ↗
7. 10.1371/journal.pgen.100221810.1371/journal.pgen.1002218 ↗
8. 10.18632/oncotarget.1080210.18632/oncotarget.10802 ↗
9. 10.1146/annurev-cellbio-092910-15403610.1146/annurev-cellbio-092910-154036 ↗
10. 10.1080/21691401.2016.118572710.1080/21691401.2016.1185727 ↗
11. 10.18632/oncotarget.476510.18632/oncotarget.4765 ↗
12. 10.1038/onc.2010.21510.1038/onc.2010.215 ↗
13. 10.1242/jcs.09969710.1242/jcs.099697 ↗
14. 10.1111/j.1349-7006.2011.01861.x10.1111/j.1349-7006.2011.01861.x ↗
15. 10.1158/0008-5472.CAN-07-057510.1158/0008-5472.CAN-07-0575 ↗
16. 10.1371/journal.pone.002383310.1371/journal.pone.0023833 ↗
17. 10.1016/j.actbio.2009.01.02610.1016/j.actbio.2009.01.026 ↗
18. 10.1016/S0304-3835(01)00824-210.1016/S0304-3835(01)00824-2 ↗
19. 10.1124/pr.56.2.610.1124/pr.56.2.6 ↗
20. 10.1016/S0024-3205(01)01372-810.1016/S0024-3205(01)01372-8 ↗
21. 10.3892/ol.2014.191810.3892/ol.2014.1918 ↗
22. 10.1016/j.bcp.2010.02.00310.1016/j.bcp.2010.02.003 ↗
23. 10.1016/j.ebiom.2016.11.02610.1016/j.ebiom.2016.11.026 ↗
24. 10.1016/j.ijpharm.2016.02.02410.1016/j.ijpharm.2016.02.024 ↗
25. 10.1021/mp100023510.1021/mp1000235 ↗
26. 10.18632/oncotarget.226710.18632/oncotarget.2267 ↗
27. 10.2147/IJN.S9446710.2147/IJN.S94467 ↗
28. 10.1016/j.jconrel.2009.09.02010.1016/j.jconrel.2009.09.020 ↗
29. 10.1200/JCO.2005.05.230810.1200/JCO.2005.05.2308 ↗
30. 10.3109/21691401.2015.112961610.3109/21691401.2015.1129616 ↗
31. 10.15252/embr.20154024410.15252/embr.201540244 ↗
32. 10.1038/nrc316910.1038/nrc3169 ↗
33. 10.18632/oncotarget.1155210.18632/oncotarget.11552 ↗
34. 10.1002/emmm.20100009510.1002/emmm.201000095 ↗
35. 10.3892/ol.2017.570010.3892/ol.2017.5700 ↗
36. 10.1111/resp.1288210.1111/resp.12882 ↗
37. 10.3109/21691401.2013.85601510.3109/21691401.2013.856015 ↗
38. 10.1016/j.phrs.2017.03.01010.1016/j.phrs.2017.03.010 ↗
39. 10.1016/j.bbamcr.2016.10.00110.1016/j.bbamcr.2016.10.001 ↗
40. 10.1016/j.neo.2014.06.00310.1016/j.neo.2014.06.003 ↗
41. 10.3109/21691401.2015.101180810.3109/21691401.2015.1011808 ↗
42. 10.4161/cc.10.23.1834610.4161/cc.10.23.18346 ↗
43. 10.1242/jcs.10011510.1242/jcs.100115 ↗
44. 10.1016/j.ceb.2005.08.00110.1016/j.ceb.2005.08.001 ↗
45. 10.1002/jcb.2317610.1002/jcb.23176 ↗
46. 10.3109/1354750X.2015.106159810.3109/1354750X.2015.1061598 ↗